CEACAM-8

CEACAM-8 Informations sur la molécule

Nom anglais	Non specific cross-reacting antigen 95	Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	1	Alias de la cible	Non-specific cross-reacting antigen NCA-95，CGM6，Carcinoembryonic Antigen Gene Family Member 6，CD66b Antigen，NCA-95，CD67，Carcinoembryonic antigen CGM6，CD66b，CEACAM8，Carcinoembryonic Antigen Related Cell Adhesion Molecule 8，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8，CD67 Antigen，CEA Cell Adhesion Molecule 8
Phase de R&D la plus avancée	Approved

Nom anglais	Non specific cross-reacting antigen 95
Alias de la cible	Non-specific cross-reacting antigen NCA-95，CGM6，Carcinoembryonic Antigen Gene Family Member 6，CD66b Antigen，NCA-95，CD67，Carcinoembryonic antigen CGM6，CD66b，CEACAM8，Carcinoembryonic Antigen Related Cell Adhesion Molecule 8，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8，CD67 Antigen，CEA Cell Adhesion Molecule 8
Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Approved

CEACAM-8 Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (2)
Étiquette
His Tag (1)His Tag & Avi Tag (1)
Marqueur
Unconjugated (1)Biotin-labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
CE8-H5224	Human	HEK293	Human CEACAM-8 / CD66b Protein, His Tag, low endotoxin (MALS verified)				Ajouter au panier
CE8-H82E9	Human	HEK293	Biotinylated Human CEACAM-8 / CD66b Protein, His,Avitag™ (SPR verified)				Ajouter au panier

Quantité totale2

CEACAM-8Contexte de la molécule

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

CEACAM-8Alias de la molécule

CEACAM8,CD66b,CD67,CGM6,NCA-95

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
90Y-DTPA-besilesomab	TLX-66	Phase 2 Clinical	Telix Pharmaceuticals Ltd	Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Besilesomab	99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx; BW-250-183	Approved	Cis Bio International Sa	Scintimun	EU	Osteomyelitis	Cis Bio International Sa	2010-01-11	Osteomyelitis	Details